Skip to main content
Top
Published in: Diagnostic Pathology 1/2016

Open Access 01-12-2016 | Research

Comparison of the types of candidate reference samples for quality control of human epidermal growth factor receptor 2 status detection

Authors: Yulong Li, Rui Zhang, Yanxi Han, Tian Lu, Jiansheng Ding, Kuo Zhang, Guigao Lin, Jiehong Xie, Jinming Li

Published in: Diagnostic Pathology | Issue 1/2016

Login to get access

Abstract

Background

Human epidermal growth factor receptor 2 (HER2) is as a target gene for trastuzumab in patients with breast cancer. Accurate determination of HER2 status and strict quality control are necessary to ensure reproducibility and accuracy of the techniques used for the determination of HER2 status.

Methods

We used three different types of samples: formalin-fixed and paraffin-embedded (FFPE) samples prepared from cell lines, agarose gel samples using cell lines, and xenograft tumor samples. One cell line for FFPE or xenografts did not overexpress HER2, while the others showed different levels of HER2 overexpression. We compared the morphology, HER2 gene amplification status, and HER2 protein expression status of these samples with those of clinical specimens.

Results

We successfully produced three kinds of samples for quality control. Cells from the cell line-sample sections were dispersed while those from the agarose gel-sample sections and xenograft tumor sample sections (prepared from the both cell lines) were concentrated in one area. The FISH results for all three kinds of samples were as expected. The IHC results of the cell line samples and xenograft tumor samples were as expected, but the staining level of the agarose gel samples, using HER2-overexpressed cell lines was weak which might be regarded as a false negative result.

Conclusions

Xenograft tumor samples might be used as an additional option for quality control in FISH and IHC. However, it might not replace the clinical specimen quality controls directly.
Appendix
Available only for authorised users
Literature
1.
go back to reference Liu W, Xu J, Liu Y, Yu X, Tang X, Wang Z, et al. Anthocyanins potentiate the activity of trastuzumab in human epidermal growth factor receptor 2-positive breast cancer cells in vitro and in vivo. Mol Med Rep. 2014;10(4):1921–6. doi:10.3892/mmr.2014.2414.PubMed Liu W, Xu J, Liu Y, Yu X, Tang X, Wang Z, et al. Anthocyanins potentiate the activity of trastuzumab in human epidermal growth factor receptor 2-positive breast cancer cells in vitro and in vivo. Mol Med Rep. 2014;10(4):1921–6. doi:10.​3892/​mmr.​2014.​2414.PubMed
3.
go back to reference Gianni L, Dafni U, Gelber RD, Azambuja E, Muehlbauer S, Goldhirsch A, et al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol. 2011;12(3):236–44. doi:10.1016/S1470-2045(11)70033-X.CrossRefPubMed Gianni L, Dafni U, Gelber RD, Azambuja E, Muehlbauer S, Goldhirsch A, et al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol. 2011;12(3):236–44. doi:10.​1016/​S1470-2045(11)70033-X.CrossRefPubMed
4.
go back to reference Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet. 2010;375(9712):377–84. doi:10.1016/S0140-6736(09)61964-4.CrossRefPubMed Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet. 2010;375(9712):377–84. doi:10.​1016/​S0140-6736(09)61964-4.CrossRefPubMed
5.
go back to reference Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2012;379(9816):633–40. doi:10.1016/S0140-6736(11)61847-3.CrossRefPubMed Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2012;379(9816):633–40. doi:10.​1016/​S0140-6736(11)61847-3.CrossRefPubMed
6.
7.
go back to reference Jimenez RE, Wallis T, Tabasczka P, Visscher DW. Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol. 2000;13(1):37–45. doi:10.1038/modpathol.3880007.CrossRefPubMed Jimenez RE, Wallis T, Tabasczka P, Visscher DW. Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol. 2000;13(1):37–45. doi:10.​1038/​modpathol.​3880007.CrossRefPubMed
8.
go back to reference Perez EA, Suman VJ, Davidson NE, Martino S, Kaufman PA, Lingle WL, et al. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol. 2006;24(19):3032–8. doi:10.1200/JCO.2005.03.4744.CrossRefPubMed Perez EA, Suman VJ, Davidson NE, Martino S, Kaufman PA, Lingle WL, et al. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol. 2006;24(19):3032–8. doi:10.​1200/​JCO.​2005.​03.​4744.CrossRefPubMed
9.
go back to reference Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007;131(1):18–43. doi:10.1043/1543-2165(2007)131[18:ASOCCO]2.0.CO;2.PubMed Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007;131(1):18–43. doi:10.​1043/​1543-2165(2007)131[18:​ASOCCO]2.​0.​CO;2.PubMed
10.
go back to reference Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31(31):3997–4013. doi:10.1200/JCO.2013.50.9984.CrossRefPubMed Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31(31):3997–4013. doi:10.​1200/​JCO.​2013.​50.​9984.CrossRefPubMed
12.
go back to reference Hammond ME, Barker P, Taube S, Gutman S. Standard reference material for Her2 testing: report of a National Institute of Standards and Technology-sponsored Consensus Workshop. Appl Immunohistochem Mol Morphol. 2003;11(2):103–6.CrossRefPubMed Hammond ME, Barker P, Taube S, Gutman S. Standard reference material for Her2 testing: report of a National Institute of Standards and Technology-sponsored Consensus Workshop. Appl Immunohistochem Mol Morphol. 2003;11(2):103–6.CrossRefPubMed
13.
go back to reference Bartlett JM, Ibrahim M, Jasani B, Morgan JM, Ellis I, Kay E, et al. External quality assurance of HER2 fluorescence in situ hybridisation testing: results of a UK NEQAS pilot scheme. J Clin Pathol. 2007;60(7):816–9. doi:10.1136/jcp.2006.040840.CrossRefPubMed Bartlett JM, Ibrahim M, Jasani B, Morgan JM, Ellis I, Kay E, et al. External quality assurance of HER2 fluorescence in situ hybridisation testing: results of a UK NEQAS pilot scheme. J Clin Pathol. 2007;60(7):816–9. doi:10.​1136/​jcp.​2006.​040840.CrossRefPubMed
14.
go back to reference Zhang R, Han Y, Huang J, Ma L, Li Y, Li J. Results of first proficiency test for KRAS testing with formalin-fixed, paraffin-embedded cell lines in China. Clin Chem Lab Med. 2014;52(12):1851–7. doi:10.1515/cclm-2014-0227.CrossRefPubMed Zhang R, Han Y, Huang J, Ma L, Li Y, Li J. Results of first proficiency test for KRAS testing with formalin-fixed, paraffin-embedded cell lines in China. Clin Chem Lab Med. 2014;52(12):1851–7. doi:10.​1515/​cclm-2014-0227.CrossRefPubMed
16.
go back to reference Martin V, Camponovo A, Ghisletta M, Bongiovanni M, Mazzucchelli L. Internal quality assurance program for ERBB2 (HER2) testing improves the selection of breast cancer patients for treatment with trastuzumab. Pathol Res Int. 2012;2012:261857. doi:10.1155/2012/261857.CrossRef Martin V, Camponovo A, Ghisletta M, Bongiovanni M, Mazzucchelli L. Internal quality assurance program for ERBB2 (HER2) testing improves the selection of breast cancer patients for treatment with trastuzumab. Pathol Res Int. 2012;2012:261857. doi:10.​1155/​2012/​261857.CrossRef
18.
go back to reference Rhodes A, Jasani B, Couturier J, McKinley MJ, Morgan JM, Dodson AR, et al. A formalin-fixed, paraffin-processed cell line standard for quality control of immunohistochemical assay of HER-2/neu expression in breast cancer. Am J Clin Pathol. 2002;117(1):81–9. doi:10.1309/4NCM-QJ9W-QM0J-6QJE.CrossRefPubMed Rhodes A, Jasani B, Couturier J, McKinley MJ, Morgan JM, Dodson AR, et al. A formalin-fixed, paraffin-processed cell line standard for quality control of immunohistochemical assay of HER-2/neu expression in breast cancer. Am J Clin Pathol. 2002;117(1):81–9. doi:10.​1309/​4NCM-QJ9W-QM0J-6QJE.CrossRefPubMed
19.
22.
go back to reference Taetle R, Jones OW, Honeysett JM, Abramson I, Bradshaw C, Reid S. Use of nude mouse xenografts as preclinical screens. Characterization of xenograft-derived melanoma cell lines. Cancer. 1987;60(8):1836–41.CrossRefPubMed Taetle R, Jones OW, Honeysett JM, Abramson I, Bradshaw C, Reid S. Use of nude mouse xenografts as preclinical screens. Characterization of xenograft-derived melanoma cell lines. Cancer. 1987;60(8):1836–41.CrossRefPubMed
24.
go back to reference Czerski L, Majors A, Ng TC, Vijayakumar S, Weichselbaum R. Growth and magnetic resonance characteristics of human squamous cell carcinoma xenografts implanted with cells suspended in Matrigel. NMR Biomed. 1993;6(5):297–301.CrossRefPubMed Czerski L, Majors A, Ng TC, Vijayakumar S, Weichselbaum R. Growth and magnetic resonance characteristics of human squamous cell carcinoma xenografts implanted with cells suspended in Matrigel. NMR Biomed. 1993;6(5):297–301.CrossRefPubMed
Metadata
Title
Comparison of the types of candidate reference samples for quality control of human epidermal growth factor receptor 2 status detection
Authors
Yulong Li
Rui Zhang
Yanxi Han
Tian Lu
Jiansheng Ding
Kuo Zhang
Guigao Lin
Jiehong Xie
Jinming Li
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Diagnostic Pathology / Issue 1/2016
Electronic ISSN: 1746-1596
DOI
https://doi.org/10.1186/s13000-016-0537-8

Other articles of this Issue 1/2016

Diagnostic Pathology 1/2016 Go to the issue